Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
纳武利尤单抗联合伊匹木单抗对比舒尼替尼一线治疗晚期肾细胞癌:来自 III 期 CheckMate 214 试验的 8 年延长随访疗效和安全性结果
期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2024.07.727
Tannir, N M; Albigès, L; McDermott, D F; Burotto, M; Choueiri, T K; Hammers, H J; Barthélémy, P; Plimack, E R; Porta, C; George, S; Donskov, F; Atkins, M B; Gurney, H; Kollmannsberger, C K; Grimm, M-O; Barrios, C; Tomita, Y; Castellano, D; Grünwald, V; Rini, B I; Jiang, R; Desilva, H; Fedorov, V; Lee, C-W; Motzer, R J